|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 28.18 USD | -0.32% |
|
-3.95% | -26.25% |
| 02-19 | Travere Therapeutics, Inc., Q4 2025 Earnings Call, Feb 19, 2026 | |
| 02-19 | Travere Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| Capitalization | 2.6B 2.24B 2.03B 1.95B 3.55B 240B 3.68B 23.83B 9.54B 114B 9.76B 9.55B 408B | P/E ratio 2026 * |
107x | P/E ratio 2027 * | 15.1x |
|---|---|---|---|---|---|
| Enterprise value | 2.56B 2.2B 2B 1.91B 3.5B 236B 3.62B 23.45B 9.39B 112B 9.6B 9.39B 402B | EV / Sales 2026 * |
3.63x | EV / Sales 2027 * | 2.48x |
| Free-Float |
98.88% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: Travere Therapeutics, Inc.
| 1 day | -0.32% | ||
| 1 week | -3.95% | ||
| Current month | -5.40% | ||
| 1 month | -11.05% | ||
| 3 months | -20.24% | ||
| 6 months | +33.24% | ||
| Current year | -26.25% |
| 1 week | 27.85 |  | 30.15 |
| 1 month | 27.01 | | 31.49 |
| Current year | 22.59 | | 40.75 |
| 1 year | 12.91 | | 42.13 |
| 3 years | 5.12 | | 42.13 |
| 5 years | 5.12 | | 42.13 |
| 10 years | 5.12 | | 42.13 |
| Manager | Title | Age | Since |
|---|---|---|---|
Eric Dube
CEO | Chief Executive Officer | 53 | 03/01/2019 |
Chris Cline
DFI | Director of Finance/CFO | 42 | 30/08/2022 |
Jula Inrig
CTO | Chief Tech/Sci/R&D Officer | 51 | 03/01/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Gary Lyons
CHM | Chairman | 75 | 17/05/2016 |
Jeffrey Meckler
CHM | Chairman | 59 | 07/06/2015 |
Tim Coughlin
BRD | Director/Board Member | 59 | 30/03/2015 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.32% | -3.95% | +43.05% | +24.42% | 2.6B | |
| -0.31% | -9.55% | +8.62% | +97.36% | 45.72B | |
| -1.85% | -7.84% | +52.40% | +10.53% | 39.82B | |
| +1.96% | +0.85% | +94.12% | +627.57% | 32.31B | |
| +3.02% | -5.50% | -5.34% | -20.62% | 26.05B | |
| +0.06% | -7.68% | +52.99% | -38.27% | 18.68B | |
| +1.56% | -2.15% | +9.23% | -30.00% | 17.17B | |
| +6.61% | -0.49% | +38.05% | +133.37% | 11.23B | |
| +1.79% | -1.91% | -19.43% | +898.70% | 11.93B | |
| +2.33% | -6.84% | +8.88% | +143.09% | 10.83B | |
| Average | +1.47% | -5.94% | +28.26% | +184.62% | 21.63B | |
| Weighted average by Cap. | +0.93% | -6.11% | +32.06% | +171.99% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 704M 606M 550M 527M 962M 64.92B 997M 6.46B 2.58B 30.96B 2.64B 2.59B 111B | 931M 801M 727M 697M 1.27B 85.83B 1.32B 8.54B 3.42B 40.93B 3.49B 3.42B 146B |
| Net income | 24.71M 21.25M 19.28M 18.49M 33.77M 2.28B 34.99M 227M 90.7M 1.09B 92.75M 90.76M 3.88B | 175M 151M 137M 131M 240M 16.16B 248M 1.61B 643M 7.71B 658M 644M 27.52B |
| Net Debt | -41.8M -35.94M -32.62M -31.28M -57.13M -3.85B -59.18M -383M -153M -1.84B -157M -154M -6.56B | -290M -249M -226M -217M -396M -26.74B -411M -2.66B -1.06B -12.75B -1.09B -1.07B -45.55B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 04/03/26 | 28.18 $ | -0.32% | 1,475,576 |
| 03/03/26 | 28.27 $ | -4.27% | 1,965,440 |
| 02/03/26 | 29.53 $ | -0.87% | 1,915,394 |
| 27/02/26 | 29.79 $ | +0.24% | 1,702,469 |
| 26/02/26 | 29.72 $ | +1.30% | 809,909 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- TVTX Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition